These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8621297)

  • 21. Dose perturbation effects in prostate seed implant brachytherapy with I-125.
    Mobit P; Badragan I
    Phys Med Biol; 2004 Jul; 49(14):3171-8. PubMed ID: 15357190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
    Lee WR; deGuzman AF; Bare RL; Marshall MG; McCullough DL
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):83-8. PubMed ID: 10656377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy.
    Patel AB; Waterman FM; Dicker AP
    Brachytherapy; 2003; 2(4):223-8. PubMed ID: 15062130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose homogeneity as a function of source activity in optimized I-125 prostate implant treatment plans.
    D'Souza WD; Meyer RR
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1120-30. PubMed ID: 11704337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Technique of intraoperative planning in prostatic brachytherapy with permanent implants of 125I or 103Pd].
    Prada Gómez PJ; Juan Rijo G; Hevia Suarez M; Abascal García JM; Abascal García R
    Arch Esp Urol; 2002 Dec; 55(10):1217-23; discussion 1223-4. PubMed ID: 12611219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of prostate implants based on postimplant treatment margin assessment.
    Mueller A; Wallner K; Merrick G; Courveau J; Sutlief S; Butler W; Gong L; Cho P
    Med Phys; 2002 Dec; 29(12):2782-7. PubMed ID: 12512711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd.
    Lindsay P; Battista J; Van Dyk J
    Med Phys; 2001 Mar; 28(3):336-45. PubMed ID: 11318315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds.
    McLaughlin P; Narayana V; Pan C; Berri S; Troyer S; Herman J; Evans V; Roberson P
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):144-50. PubMed ID: 16243441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is intraoperative nomogram-based overplanning of prostate implants necessary?
    D'Souza WD; Lee HK; Palmer MB; Smith LG; Pollack A
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):462-7. PubMed ID: 12738321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
    Todor DA; Barani IJ; Lin PS; Anscher MS
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-species prostate implant treatment plans incorporating 192Ir and 125I using a Greedy Heuristic based 3D optimization algorithm.
    Chaswal V; Yoo S; Thomadsen BR; Henderson DL
    Med Phys; 2007 Feb; 34(2):436-44. PubMed ID: 17388159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
    Meigooni AS; Luerman CM; Sowards KT
    Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
    Butler WM; Merrick GS; Dorsey AT; Lief JH
    Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential role of various dosimetric quality indicators in prostate brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?
    Waterman FM; Dicker AP
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):293-9. PubMed ID: 12909246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prescription dose in permanent (131)Cs seed prostate implants.
    Yue N; Heron DE; Komanduri K; Huq MS
    Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A nomograph for permanent implants of palladium-103 seeds.
    Anderson LL; Moni JV; Harrison LB
    Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):129-35. PubMed ID: 8365933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idealized line source configuration for permanent 125I prostate implants.
    Leclerc G; Lavallée MC; Tubic D; Métivier J; Vigneault E; Beaulieu L
    Radiother Oncol; 2004 Aug; 72(2):213-20. PubMed ID: 15297139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.